Saltar al contenido
Merck

The therapeutic effects of human adipose-derived stem cells in a rat cervical spinal cord injury model.

Stem cells and development (2014-05-08)
Mallappa K Kolar, Paul J Kingham, Liudmila N Novikova, Mikael Wiberg, Lev N Novikov
RESUMEN

Spinal cord injury triggers a cascade of degenerative changes leading to cell death and cavitation. Severed axons fail to regenerate across the scar tissue and are only capable of limited sprouting. In this study, we investigated the effects of adult human adipose-derived stem cells (ASC) on axonal regeneration following transplantation into the injured rat cervical spinal cord. ASC did not induce activation of astrocytes in culture and supported neurite outgrowth from adult rat sensory dorsal root ganglia neurons. After transplantation into the lateral funiculus 1 mm rostral and caudal to the cervical C3-C4 hemisection, ASC continued to express brain-derived neurotrophic factor, vascular endothelial growth factor, and fibroblast growth factor-2 for 3 weeks but only in animals treated with cyclosporine A. Transplanted ASC stimulated extensive ingrowth of 5HT-positive raphaespinal axons into the trauma zone with some terminal arborizations reaching the caudal spinal cord. In addition, ASC induced sprouting of raphaespinal terminals in C2 contralateral ventral horn and C6 ventral horn on both sides. Transplanted cells also changed the structure of the lesion scar with numerous astrocytic processes extended into the middle of the trauma zone in a chain-like pattern and in close association with regenerating axons. The density of the astrocytic network was also significantly decreased. Although the transplanted cells had no effect on the density of capillaries around the lesion site, the activity of OX42-positive microglial cells was markedly reduced. However, ASC did not support recovery of forelimb function. The results suggest that transplanted ASC can modify the structure of the glial scar and stimulate axonal sprouting.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Glicina, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Glicina, suitable for electrophoresis, ≥99%
Sigma-Aldrich
L-Glutamina, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
Glicina, BioUltra, for molecular biology, ≥99.0% (NT)
Sigma-Aldrich
Forskolina, from Coleus forskohlii, ≥98% (HPLC), powder
Sigma-Aldrich
L-Glutamina, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Forskolina, For use in molecular biology applications
Sigma-Aldrich
Glicina, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
SAFC
L-Glutamina
SAFC
Glicina
Sigma-Aldrich
L-Glutamina, BioUltra, ≥99.5% (NT)
USP
Glicina, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Glicina, BioXtra, ≥99% (titration)
Sigma-Aldrich
Glicina, 99%, FCC
Sigma-Aldrich
L-Glutamina
Sigma-Aldrich
L-Glutamina, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Glicina, ACS reagent, ≥98.5%
Supelco
Glicina, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glicina, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)
Supelco
Forskolina, analytical standard
Supelco
Glicina, analytical standard, for nitrogen determination according to Kjeldahl method
Supelco
L-Glutamina, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glicina, puriss. p.a., reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance)
Glicina, European Pharmacopoeia (EP) Reference Standard
Supelco
Glicina, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-Glutamina, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Glicina, tested according to Ph. Eur.